Remetinostat is under clinical development by Medivir and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Remetinostat’s likelihood of approval (LoA) and phase transition for Basal Cell Carcinoma (Basal Cell Epithelioma) took place on 06 Jan 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Remetinostat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Remetinostat overview

Remetinostat (SHP-141) is under development for the treatment of mycosis fungoides (MF) type early-stage cutaneous T-cell lymphoma, squamous cell carcinoma and basal cell carcinoma. It is administered through topical route. The drug candidate is SHAPE (suberohydroxamic acid phenyl ester) molecule which acts by targeting histone deacetylases (HDAC). It was also under development for the treatment of plaque psoriasis and alopecia areata.

Medivir overview

Medivir is a pharmaceutical company. It is engaged in drug discovery and development of treatments for cancer.The company offers products under development for the treatment of cutaneous T-cell lymphoma, osteoarthritis, solid tumors, hepatocellular carcinoma and acute myeloid leukemia. Medivir also provides products in partnership with other pharmaceutical companies for the disease areas of hepatitis C and labial herpes. The company’s products are in Phase I and phase II development stages. It conducts research and development in the areas of infectious diseases, bone disorders and cancer. The company operates through a research unit in Huddinge, Sweden. Medvir is headquartered in Huddinge, Sweden.

Quick View Remetinostat LOA Data

Report Segments
  • Innovator
Drug Name
  • Remetinostat
Administration Pathway
  • Topical
Therapeutic Areas
  • Dermatology
  • Immunology
  • Oncology
Key Developers
  • Sponsor Company: Medivir
  • Originator: Massachusetts General Hospital, Harvard University and Dana-Farber Cancer Institute
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.